`
`BEFORE THE PATENT TRIAL AND APPEAL BOARD
`
`MYLAN PHARMACEUTICALS INC.,
`Petitioner,
`
`v.
`
`SANOFI-AVENTIS DEUTSCHLAND GmbH,
`Patent Owner.
`
`Case IPR2018-01675
`Patent No. 8,603,044
`
`DECLARATION OF ANNA E. DWYER IN SUPPORT OF MOTION FOR
`PRO HAC VICE ADMISSION UNDER 37 C.F.R. § 42.10
`
`Sanofi Exhibit 2221.001
`Mylan v. Sanofi
`IPR2018-01675
`
`
`
`
`
`DECLARATION OF ANNA E. DWYER IN SUPPORT OF MOTION FOR
`PRO HAC VICE ADMISSION
`
`I, Anna E. Dwyer, am over eighteen years of age and would be competent to
`
`testify as to the matters set forth herein if called upon to do so.
`
`1.
`
`I am an attorney in the law firm of Weil, Gotshal & Manges LLP. I
`
`have over five years experience as a patent litigator and have represented clients in
`
`numerous complex patent litigation cases in various United States District Courts.
`
`My biography is attached hereto as Ex. 2222.
`
`2.
`
`I am familiar with the subject matter at issue in this proceeding. I
`
`am counsel for Patent Owner in the co-pending litigation Sanofi-Aventis U.S. LLC
`
`v. Mylan N.V., Case No. 17-cv-9105 (D.N.J.), in which U.S. Patent No. 8,603,044
`
`was asserted in the complaint. Furthermore, I have an undergraduate Bachelor of
`
`Science degree in Chemistry and have completed graduate coursework in organic
`
`chemistry. I also have five years of experience as a patent litigation attorney. I
`
`have been involved in numerous patent litigations and have experience with a wide
`
`variety of complex technologies relating to pharmaceuticals.
`
`3.
`
`I am a member in good standing of the state bar of New York and
`
`the United States Court of Appeals for the Federal Circuit.
`
`4.
`
`I have not been suspended or disbarred from practice before any
`
`court or administrative body.
`
`5.
`
`I have never had an application for admission to practice before any
`
`
`
`1
`
`Sanofi Exhibit 2221.002
`Mylan v. Sanofi
`IPR2018-01675
`
`
`
`court or administrative body denied.
`
`6.
`
`No sanction or contempt citation has been imposed against me by
`
`any court or administrative body.
`
`7.
`
`I have read and will comply with the Office Patent Trial Practice
`
`Guide and the Board’s Rules of Practice for Trials set forth in part 42 of 37 C.F.R.
`
`8.
`
`I will be subject to the USPTO Rules of Professional Conduct set
`
`forth in 37 C.F.R. §§ 11.101 et seq. and disciplinary jurisdiction under 37 C.F.R. §
`
`11.19(a).
`
`I declare under penalty of perjury that the foregoing Declaration is true and
`
`correct; and further that these statements are made with the knowledge that willful
`
`false statements and the like are punishable by fine or imprisonment, or both, under
`
`Section 1001 of Title 18 of the United States Code.
`
`Dated: August 16, 2019
`
`Respectfully submitted,
`
`/Anna E. Dwyer/
`Anna E. Dwyer
`Weil, Gotshal & Manges LLP
`767 Fifth Avenue
`New York, NY 10153
`T: 212-310-8285
`anna.dwyer@weil.com
`
`2
`
`Sanofi Exhibit 2221.003
`Mylan v. Sanofi
`IPR2018-01675
`
`